Bladder cancer trial pits radiotherapy against standard immunotherapy

NCT ID NCT07268339

Not yet recruiting Disease control Sponsor: The Christie NHS Foundation Trust Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 3 trial compares radiotherapy with a radiosensitiser to the standard BCG immunotherapy for high-risk non-muscle invasive bladder cancer. About 328 patients will be randomly assigned to one of the two treatments after tumor removal. The goal is to see which approach better prevents cancer from coming back or getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiotherapy with radiosensitisation (gemcitabine, mitomycin C/fluorouracil, or carbogen/nicotinamide)
What this could lead to: If successful, this could offer a more effective alternative to BCG for high-risk bladder cancer, reducing recurrence and the need for bladder removal.
What could go wrong: This is an early-stage trial with 328 participants, and radiotherapy may cause side effects like bladder or bowel irritation. It may not prove superior to BCG.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Non-Muscle Invasive Bladder Neoplasms superficial urinary bladder carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER

Contacts and locations

Locations

The Christie

Manchester, M20 4BX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.